SCHEMBL8618909

SCHEMBL8618909

N#Cc1ccc(COc2ccccc2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.85
APP P05067 1/20 0.60
SMPD1 P17405 1/20 0.57
AR P10275 1/20 0.56
CYP19A1 P11511 1/20 0.56
RAB9A P51151 3/20 0.55
NPC1 O15118 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 1/20 0.54
LMNA P02545 1/20 0.52
CYP1A2 P05177 1/20 0.52
PTGS1 P23219 1/20 0.52
SLC6A2 P23975 1/20 0.52
CYP2C19 P33261 1/20 0.52
PTGS2 P35354 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HIF1A Q16665 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
BCHE P06276 1/20 0.52
FFAR1 O14842 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL403151 0.92 MAOB (1.00) MAOBARCYP19A1RAB9ASMN1; SMN2
SCHEMBL29741480 0.90 MAOB (0.81) MAOBAPPSMPD1ARCYP19A1
SCHEMBL18664184 0.90 MAOB (0.81) MAOBAPPSMPD1ARCYP19A1
SCHEMBL7311874 0.89 MAOB (0.86) MAOBSMPD1ARCYP19A1RAB9A
SCHEMBL1249162 0.89 MAOB (0.80) MAOBARCYP19A1RAB9ABCHE
SCHEMBL20240306 0.89 MAOB (0.80) MAOBARCYP19A1RAB9ABCHE
SCHEMBL7372943 0.87 MAOB (0.89) MAOBARCYP19A1RAB9ASMN1; SMN2
SCHEMBL28961976 0.87 MAOB (0.89) MAOBARCYP19A1RAB9ASMN1; SMN2
SCHEMBL850999 0.85 APP (0.78) MAOBAPPRAB9ASMN1; SMN2GAA
SCHEMBL8806782 0.85 MAOB (0.78) MAOBARRAB9ANPC1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062002-B2 Substituted pyridine derivatives as FabI inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-06-23 US disclosed
US-9062002-B2 Substituted pyridine derivatives as FabI inhibitors AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-06-23 US disclosed
US-20140336153-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS AURIGENE DISCOVERY TECH LTD (IN) 2014-11-13 US disclosed
US-20140336153-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS AURIGENE DISCOVERY TECH LTD (IN) 2014-11-13 US disclosed
WO-2013080222-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2013-06-06 WO disclosed
US-20120283266-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE ORYZON GENOMICS S.A. (ES) 2012-11-08 US disclosed
WO-2010043721-A1 OXIDASE INHIBITORS AND THEIR USE ORYZON GENOMICS, S.A. (ES) 2010-04-22 WO disclosed
US-5777172-A Process for the preparation of benzophenthiones and benzophenones ZENECA LIMITED (GB) 1998-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336153-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS F12, FAR1, NQO2 MAOB 270/4885APP 1949/4885SMPD1 784/4885
US-20120283266-A1 LYSINE SPECIFIC DEMETHYLASE-1 INHIBITORS AND THEIR USE JMJD6, KDM3A, KDM1A MAOB 186/4885APP 4824/4885SMPD1 343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.